GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Institutional Ownership

SELLAS Life Sciences Group (FRA:RXK3) Institutional Ownership : 5.42% (As of Jun. 19, 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SELLAS Life Sciences Group's institutional ownership is 5.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SELLAS Life Sciences Group's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SELLAS Life Sciences Group's Float Percentage Of Total Shares Outstanding is 99.78%.


SELLAS Life Sciences Group Institutional Ownership Historical Data

The historical data trend for SELLAS Life Sciences Group's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Institutional Ownership Chart

SELLAS Life Sciences Group Historical Data

The historical data trend for SELLAS Life Sciences Group can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 8.33 8.48 6.45 5.74 6.49 4.80 4.79 5.03 5.42 5.42

SELLAS Life Sciences Group Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


SELLAS Life Sciences Group (FRA:RXK3) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines